Nymox Pharmaceutical Corporation is a biopharmaceutical company that researches and develops drugs for the elderly population worldwide. Fexapotide Triflutate (NX-1207), the company's leading drug candidate, has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, in addition to low grade localized prostate cancer, and is in preclinical studies for hepatocellular carcinoma. The company also develops NicAlert and TobacAlert tests that use urine or saliva to detect the use of tobacco products and offers AlzheimAlert, which aids physicians in diagnosing Alzheimer's disease, as well as researching and developing drug treatments.